OTTAWA – Canadian health authorities announced Friday they have given approval to a second generic alternative to the popular diabetes medication Ozempic, expanding treatment options for patients across the country.
The regulatory approval went to Apotex, a Canada-based pharmaceutical company, for their version of semaglutide, the active ingredient in Ozempic. This marks the second time Canadian officials have authorized a copycat version of the highly successful diabetes treatment originally developed by Danish pharmaceutical company Novo Nordisk.
The decision by Canadian health regulators could provide patients with more affordable access to the diabetes medication that has gained widespread attention not only for blood sugar management but also for its weight loss effects.
